Fisker Announces Timing of First Quarter 2023 Results and Webcast

Fisker Inc. (NYSE: FSR) ("Fisker") driven by a mission to create the world's most emotional and sustainable electric vehicles today announced that it will report its first quarter 2023 financial results before the market opens on Tuesday, May 9, 2023. The release will be followed by a conference call at 5:00 a.m. PT (8:00 a.m. ET). Speakers on the call will be Henrik Fisker, Chairman and Chief Executive Officer; Dr. Burkhard Huhnke, Chief Technology Officer; and Dr. Geeta Gupta-Fisker, Chief Operating Officer and Chief Financial Officer of Fisker Inc.

The conference call can be accessed via a live webcast accessible on the Events and Presentations page of Fisker's Investor Relations website: https://investors.fiskerinc.com/ . An archive of the webcast will be available shortly after the call and will remain on the website for 12 months thereafter.

In addition, Fisker will once again provide shareholders the ability to submit and upvote questions to management through a shareholder Q&A platform. To submit questions ahead of earnings, please visit the Say platform link available on our website; shareholders at brokers with Say can participate directly in their investing app or broker website. The Q&A platform will remain open until 24 hours before the earnings call and can also be accessed in the Events & Presentations section of Fisker's IR website. Management intends to respond to a selection of questions during the Q&A portion of the call.

About Fisker Inc.

California-based Fisker Inc. is revolutionizing the automotive industry by developing the most emotionally desirable and eco-friendly electric vehicles on Earth. Passionately driven by a vision of a clean future for all, the company is on a mission to become the No. 1 e-mobility service provider with the world's most sustainable vehicles. To learn more, visit www.FiskerInc.com – and enjoy exclusive content across Fisker's social media channels: Facebook , Instagram , Twitter , YouTube , and LinkedIn .

Download the revolutionary new Fisker mobile app from the App Store or Google Play store.

Fisker Inc. Communications:

Matthew DeBord
Sr. Director, Communications Strategy & Storytelling
mdebord@fiskerinc.com

Rebecca Lindland
Director, Communications
rlindland@fiskerinc.com

Franziska Queling
Regional Head of Public Relations Europe
fqueling@fiskerinc.com

Investor Relations:

Frank Boroch, VP of Investor Relations
fboroch@fiskerinc.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis.

The QIAstat-Dx Gastrointestinal Panel 2 takes about an hour to simultaneously look for up to 16 clinically relevant bacterial, viral and parasitic pathogens that cause most GI infections. Acute infectious gastroenteritis is a common reason for hospitalizations and outpatient physician visits in the U.S., with an estimated 180 million cases per year. [1]

The panel leverages QIAstat-Dx's ability to quickly multiply many genetic targets using real-time PCR technology in the same reaction – an important advance compared to traditional microbiological testing, which often requires samples to be incubated for at least 24 hours and up to 10 days of specimen collection. Software interprets signals from the reaction and provides positive or negative results for each pathogen. QIAstat-Dx additionally provides easy-to-view cycle threshold (Ct) values and amplification curves that can offer additional insights not available with end-point PCR or other techniques.

"The QIAstat-Dx Gastrointestinal Panel 2 allows medical professionals to identify which GI pathogen they are dealing with quickly," said Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. "This is QIAGEN's answer to two major problems in treating GI infections: diagnosis of overlapping symptoms and laborious testing methods."

"It can be very difficult to clinically distinguish between viral, bacterial and parasitic causes of GI illness. We can easily set up and get a full panel of results back faster than culture and microscopy, and access to Ct values for each detected pathogen can provide valuable information when interpreting when interpreting multiple pathogen detections," added Romney Humphries, Ph.D., professor of Pathology, Microbiology, and Immunology and division director for Laboratory Medicine at Vanderbilt University Medical Center in the U.S. about the clinical utility of QIAstat-Dx.

The new panel expands QIAGEN's U.S. menu for syndromic testing, building on the use of the QIAstat-Dx Respiratory Panel Plus that can identify 21 pathogens causing respiratory infections from viral and bacterial pathogens. Both Panels are available as cost-efficient, single-use cartridges that slot easily into the QIAstat-Dx Analyzer 1.0. As they contain all reagents, set up takes less than a minute and requires no precision pipetting.

The U.S. launch supports healthcare providers with diagnosing and treating patients quickly and accurately. They will be able to quickly isolate those at risk of transmitting infections and identify negative cases sooner, reducing the burden of unnecessary testing and treatment costs on the healthcare system and patients. Syndromic tests have also been shown to improve the detection of co-infections, reducing the need for additional testing like endoscopies. By providing fast results, syndromic testing enables healthcare providers to make informed decisions and discontinue empiric antibiotic treatment when viral pathogens are detected, reducing overall antibiotic usage and supporting the goal of responsible antimicrobial stewardship.

Syndromic testing with cloud-based connectivity and epidemiological insights

QIAstat-Dx solutions and syndromic tests to support diagnosing diseases are available in more than 100 countries worldwide, including the U.S. and many across Europe. More than 4,000 cumulative systems were installed worldwide at the end of 2023. Hospitals, laboratories and clinics value the QIAstat-Dx range as an easy-to-use automated solution for the reliable detection of various pathogens.

QIAstat-Dx is available in two formats: The QIAstat-Dx version that brings together up to four Analytical Modules into one integrated system, and the QIAstat-Dx Rise higher-capacity version that provides comprehensive testing for up to 160 tests per day using eight Analytical Modules. QIAstat-Dx Rise is available with CE-IVD marking in Europe and other countries that accept this marking.

With a QIAstat-Dx Connectivity plan, QIAstat-Dx connects to the QIAsphere cloud-based platform that provides remote monitoring of the instruments and test status, allowing customers to receive push notifications on their personal devices. It can monitor an unlimited number of instruments across different hospitals or satellite labs, reducing system downtime and enabling fast and accurate syndromic testing. Connectivity is achieved through the Qbase hub, which can be connected to QIAstat-Dx in minimal time through hospitals' LAN or Wi-Fi network, ensuring sensitive patient data remains within the hospital network.

QIAsphere also allows users to view and export reports on real-time local, regional and global epidemiology data through QIAsphere Insights to support epidemiological surveillance . Further, with the recent release of a medical reference app for QIAstat-Dx users, the Pathogen Guide , QIAstat-Dx is poised as a leader in digital diagnostic technology for customers around the world.

Learn more about QIAstat-Dx and the Gastrointestinal Panel 2 at https://www.qiagen.com/applications/syndromic-testing/benefits/gastrointestinal-care

About QIAGEN

Qiagen N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com .

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: Qiagen N.V.
Category: Corporate

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Best-Selling Cessna Citation Latitude and Flagship Citation Longitude to Offer New Advanced Avionics Features

Best-Selling Cessna Citation Latitude and Flagship Citation Longitude to Offer New Advanced Avionics Features

Textron Aviation today announced advanced Garmin G5000 avionics enhancements coming to the best-selling mid-size business jet, the Cessna Citation Latitude, and the flagship of the Citation family of jets, the Citation Longitude. Textron Aviation's investments in the popular business jets, based on customer feedback, will offer greater performance and improved user experience to pilots in the new Latitude jets beginning in 2025 and the new Longitude jets in 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527032307/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Element79 Gold: Ongoing Commitment to Community Empowerment

Element79 Gold: Ongoing Commitment to Community Empowerment

(TheNewswire)

Element79 Gold Corp.

Chachas, Arequipa, Peru

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Gravity Survey Results Identify High Impact Near Deposit Massive Sulphide Exploration Targets at its Lagoa Salgada VMS Project, in Portugal

Gravity Survey Results Identify High Impact Near Deposit Massive Sulphide Exploration Targets at its Lagoa Salgada VMS Project, in Portugal

  • New High-Resolution gravity survey suggests potential to rapidly expand Massive Sulphide Mineralization at current Venda Nova North and South Deposits
  • Multiple additional gravity anomalies identified to potentially add to the Massive Sulphide Ore Bodies near Venda Nova
  • EDM's Option to gain a 15% interest in the Project extended to September 30, 2024 due to upcoming elections and government change

Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASDRF)(FRA:2D9) ("Ascendant" or the "Company") is pleased to announce the results of its recent high-resolution gravity survey completed over the Venda Nova North and South Deposits at its Lagoa Salgada VMS Project, in Portugal

Key Highlights

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Ascendant Provides Summary of 2023 Achievements and Outlook for 2024

Ascendant Provides Summary of 2023 Achievements and Outlook for 2024

Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASDRF)(FRA:2D9) ("Ascendant" or the "Company"), is pleased to provide a summary of the significant milestones achieved during 2023 and looks forward to another year of continued de-risking and key value creation objectives in 2024 for its Lagao Salgada polymetallic project in Portugal

Key Milestones Delivered in 2023

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Real Matters Reports Second Quarter Financial Results

(all amounts are expressed in millions of U.S. dollars, excluding per share amounts and unless otherwise stated)

Real Matters Inc. (TSX: REAL) ("Real Matters" or the "Company"), a leading network management services platform for the mortgage and insurance industries, today announced its financial results for the second quarter ended March 31, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters Announces Changes to its Board of Directors

Real Matters Inc. ("Real Matters" or the "Company"), a leading network management services provider for the mortgage lending and insurance industries, today announced that Lisa Melchior will be stepping down after serving on the Real Matters Board since 2017. The Company also announced the appointment of Kay Brekken to its Board of Directors. Ms. Brekken will succeed Ms. Melchior as a member of the Compensation, Nomination and Governance Committee. The changes are effective May 7, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507719548/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Announce Second Quarter Fiscal 2024 Financial Results on May 7, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will announce its second quarter fiscal 2024 financial results via news release on Tuesday, May 7, 2024, before market open.

Conference Call and Webcast

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters Reports First Quarter Financial Results

(all amounts are expressed in millions of U.S. dollars, excluding per share amounts and unless otherwise stated)

Real Matters Inc. (TSX: REAL) ("Real Matters" or the "Company"), a leading network management services platform for the mortgage and insurance industries, today announced its financial results for the first quarter ended December 31, 2023.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Hold Virtual Annual General Meeting on February 8, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will be holding its Annual General Meeting (the "Meeting") on Thursday, February 8, 2024 at 10:00 a.m. (Eastern Standard Time). The Meeting will be conducted online only, via audio webcast at: www.virtualshareholdermeeting.com/realmatters2024 .

Registered and non-registered shareholders entitled to vote at the Meeting may vote by proxy in advance of the Meeting. However, only registered shareholders and duly appointed proxyholders (including non-registered shareholders who have duly appointed themselves as proxyholder) will be entitled to vote at the Meeting during the live audio webcast. Non-registered shareholders who have not duly appointed themselves as proxyholders will be able to attend the Meeting and ask questions, but will not be able to vote. Guests will be able to attend the Meeting but will not be able to submit questions, vote their shares (if any) or otherwise participate in the Meeting. Please note that registered shareholders will need the 16-digit control number indicated on the form of proxy accompanying their Notice of Meeting to log on to the Meeting as a "Shareholder". Duly appointed proxyholders will need the Appointee Name and 8-character Appointee Identification Number to log on to the Meeting as a "Proxyholder / Appointee". Otherwise, shareholders or duly appointed proxyholders, as applicable, will have to log on as "Guests". Please refer to the Company's Management Information Circular in the Investor Relations section of our website for additional details on how to log on to the Meeting.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Announce First Quarter Fiscal 2024 Financial Results on February 1, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will announce its first quarter fiscal 2024 financial results via news release on Thursday, February 1, 2024, before market open.

Conference Call and Webcast

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×